Find Reports
Select Report Type
Reimbursement Review
Displaying 326 - 350 of 1258
Please scroll or swipe to the right to view the full content.
| Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|
| Cablivi | caplacizumab | Acquired thrombotic thrombocytopenic purpura (aTTP) | Do not reimburse | Complete | SR0633-000 | |||
| Soliris | eculizumab | Neuromyelitis optica spectrum disorder | Reimburse with clinical criteria and/or conditions | Complete | SR0640-000 | |||
| Aimovig | erenumab | Migraine | Reimburse with clinical criteria and/or conditions | Complete | SR0578-000 | |||
| Vocabria and Cabenuva | cabotegravir sodium cabotegravir-rilpivirine | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | SR0628-000 | |||
| Mayzent | siponimod | Secondary progressive multiple sclerosis | Reimburse with clinical criteria and/or conditions | Complete | SR0631-000 | |||
| Stelara/Stelara I.V | ustekinumab | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | SR0627-000 | |||
| Vascepa | icosapent ethyl | Ischemic events in statin-treated patients | Reimburse with clinical criteria and/or conditions | Complete | SR0619-000 | |||
| Tecentriq & Avastin | Atezolizumab & Bevacizumab | NSQ-NSCLC | Do not reimburse | Complete | PC0155-000 | |||
| Cuvposa | glycopyrrolate | chronic severe drooling, neurologic (pediatric) | Do not reimburse | Complete | SR0613-000 | |||
| Kisqali | Ribociclib | HR+, HER2- advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0194-000 | |||
| Adcetris | Brentuximab Vedotin | peripheral T-cell lymphoma (PTCL) | Reimburse | Complete | PC0199-000 | |||
| Crysvita | burosumab | Treatment of X-Linked Hypophosphatemia | Reimburse with clinical criteria and/or conditions | Complete | SR0602-000 | |||
| Contrave | naltrexone hydrochloride and bupropion hydrochloride | Chronic weight management in adults | Do not reimburse | Complete | SR0610-000 | |||
| Beovu | brolucizumab | Macular degeneration, age-related | Reimburse with clinical criteria and/or conditions | Complete | SR0632-000 | |||
| Xospata | Gilteritinib | Reimburse with clinical criteria and/or conditions | Complete | PC0202 -000 | ||||
| Entyvio | vedolizumab | Ulcerative Colitis | Reimburse with clinical criteria and/or conditions | Complete | SR0635-000 | |||
| Erleada | Apalutamide | metastatic castration-sensitive prostate cancer (mCSPC) | Reimburse with clinical criteria and/or conditions | Complete | PC0200-000 | |||
| Cabometyx | Cabozantinib | HCC | Reimburse with clinical criteria and/or conditions | Complete | PC0186-000 | |||
| Dupixent | dupilumab | atopic dermatitis | Reimburse with clinical criteria and/or conditions | Complete | SR0636-000 | |||
| Benlysta | Belimumab | systemic lupus erythematosus | Do not reimburse | Complete | SR0616-000 | |||
| Kisqali | Ribociclib with Fulvestrant | +Fulvestrant for HR+, HER2- advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0195-000 | |||
| Nubeqa | Darolutamide | non-metastatic castration resistant prostate cancer (nmCRPC) | Reimburse with clinical criteria and/or conditions | Complete | PC0196-000 | |||
| Keytruda | Pembrolizumab | Renal Cell Carcinoma (RCC) | Reimburse with clinical criteria and/or conditions | Complete | PC0185-000 | |||
| Mylotarg | Gemtuzumab Ozogamicin | Acute Myeloid Leukemia (AML) | Reimburse | Complete | PC0190-000 | |||
| Rydapt | Midostaurin | Systemic Mastocytosis | Do not reimburse | Complete | PC0193-000 |
Health Technology Review
Displaying 326 - 350 of 589
Please scroll or swipe to the right to view the full content.
Horizon Scan
Displaying 101 - 111 of 111
Projects in Progress
Displaying 26 - 40 of 40
View All Reports
Displaying 326 - 350 of 2093
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|---|
| nirmatrelvir/ritonavir | Reimbursement Review | Complete | SR0808-000 | ||||
| Optimal installation of DI equipment | Health Technology Review | In Progress | CM0013-000 | ||||
| Appraisal of RWE submitted for health technology assessment | Health Technology Review | In Progress | MG0028-000 | ||||
| PET-CT Comparisons 2020-2024 | Health Technology Review | In Progress | CM0006-000 | ||||
| Cystic Fibrosis | Health Technology Review | In Progress | HM0005-000 | ||||
| Natural Cycles App as Contraception | Horizon Scan | Health Technology Update | In Progress | EN0057-000 | |||
| Newborn screening - Drugs for Rare Diseases Strategy | Health Technology Review | Technology Review | In Progress | HC0079-000 | |||
| Methodology for Ethics Analysis in Pharmaceutical Reimbursement Reviews | Health Technology Review | In Progress | MG0027-000 | ||||
| Drug Shortages in Canada - Delphi Panel | Health Technology Review | Technology Review | In Progress | HC0074-000 | |||
| Pharmaceutical Reviews Update — Issue 48 | Reimbursement Review | Pharmaceutical Review Update | |||||
| Endometrial Cancer | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0045-000 | |||
| NSCLC without actionable oncogenic alteration | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0046-000 | |||
| cannabidiol | Reimbursement Review | Complete | SR0799-000 | ||||
| Choline Supplementation for Infants, Children, and Pregnant People | Health Technology Review | Rapid Review | Completed | RC1531-000 | |||
| Interferons, Glatiramer Acetate, and Minocycline for Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome | Health Technology Review | Rapid Review | Completed | RC1540-000 | |||
| Nabilone for Chronic Non-Cancer Pain | Health Technology Review | Rapid Review | Completed | RC1539-000 | |||
| Infliximab for Immune Checkpoint Inhibitor Therapy-Related Toxicities | Health Technology Review | Rapid Review | Completed | RC1536-000 | |||
| ravulizumab | Reimbursement Review | Complete | SR0785-000 | ||||
| Minimum Retesting Intervals for Lab Tests | Canada’s Drug Agency partnered with Choosing Wisely Canada to host a multidisciplinary panel of experts to provide guidance on the minimum retesting intervals of laboratory tests that are commonly repeated in hospitals, health authorities, and community laboratories across the country. | Health Technology Review | Technology Review | Completed | HC0078-000 | ||
| treosulfan | Reimbursement Review | Complete | PC0324-000 | ||||
| Anticytokine Therapy and Corticosteroids for Cytokine Release Syndrome and for Neurotoxicity Following T-Cell Engager or CAR T-Cell Therapy | Health Technology Review | Rapid Review | Completed | RC1534-000 | |||
| fidanacogene elaparvovec | Reimbursement Review | Complete | SG0802-000 | ||||
| Virtual Medicine Wards and Hospital-at-Home Programs | Virtual wards, also known as hospital-at-home programs, support the provision of inpatient-level acute medical care in a patient’s home. Our Horizon Scan presents existing evaluations of virtual ward and hospital-at-home programs for early supported discharge. | Horizon Scan | Health Technology Update | Completed | EN0056-000 | ||
| Cutaneous Melanoma | Reimbursement Review | Provisional Funding Algorithm | Active | PH0042-000 | |||
| Point-of-Care Tests for COVID-19 and Influenza in Canada | Horizon Scan | Health Technology Update | Completed | EN0055-000 |